Clinical Trial Update: Open-Label Pilot Study of OPTUNE® With High Density Transducer Arrays for the Treatment of Recurrent GBM [Phase 2]

View source ↗

Summary

This document reports the completion of an open-label Phase 2 pilot study evaluating the OPTUNE TTFields device with high-density transducer arrays for recurren…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma

Drugs mentioned

• OPTUNE

Snippet

Sponsor: NovoCure GmbH | Conditions: Glioblastoma Multiforme | Phase 2 | Status: COMPLETED